Mantle Cell Lymphoma | Specialty

The mantle cell lymphoma condition center is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma. Read more at OncLive.

Experts Prepare for Several Key MCL Presentations at ASH 2025

December 5th 2025

Hematology experts share the MCL abstracts they’re most looking forward to seeing at the 2025 ASH Annual Meeting.

The OncFive: Top Oncology Articles for the Week of 11/23

November 29th 2025

The FDA approved a new option in resectable gastric cancer, and a new agent is under priority review in mantle cell lymphoma.

FDA Grants Priority Review to Sonrotoclax for R/R Mantle Cell Lymphoma

November 26th 2025

Sonrotoclax is under priority review by the FDA for the treatment of adult patients with relapsed or refractory, BTK inhibitor–pretreated MCL.

Evolving Approaches With BTK Inhibition and Targeted Therapy Seek to Improve Outcomes in High-Risk MCL

November 26th 2025

Christine Ryan, MD, discusses the limitations of current MCL treatment strategies, advances in treatment, and the evolving role of BTK inhibition.

European Commission Approves Liso-Cel for R/R Mantle Cell Lymphoma

November 25th 2025

Liso-cel was approved in the EU for relapsed/refractory MCL after at least 2 lines of therapy, including a BTK inhibitor.

Venetoclax-Enhanced RBAC Shows Promise in High-Risk Mantle Cell Lymphoma

November 20th 2025

Carlo Visco, MD, discusses phase 2 FIL_V-RBAC results showing venetoclax plus RBAC achieved a meaningful PFS and manageable toxicity in high-risk MCL.

Dr Visco on Ongoing Research to Optimize Upfront MCL Therapy

November 13th 2025

Carlo Visco, MD, discussed notable ongoing MCL research and the emerging challenge of optimally sequencing therapies for the management of this disease.

Dr Visco on Unmet Needs for Patients With Mantle Cell Lymphoma

November 6th 2025

Carlo Visco, MD, explains the need to study treatment outcomes and develop novel therapies for patients with mantle cell lymphoma harboring TP53 mutations.

Dr Visco on the Role of RBAC Dose Reductions for High-Risk MCL

October 30th 2025

Carlo Visco, MD, highlights the clinical relevance of reducing the dose of certain RBAC components when administering this regimen in high-risk MCL.

Dr Dreyling on the Evolving Role of BTK Inhibitors in MCL Management

October 29th 2025

Martin Dreyling, MD, speculated on the future role of BTK inhibitors either alone or in non-cytotoxic chemotherapy combinations for patients with MCL.

Dr Visco on the Efficacy and Safety of Venetoclax Plus RBAC in High-Risk MCL

October 23rd 2025

Carlo Visco, MD, discussed patient characteristics, efficacy data, and safety findings from the FIL_V-RBAC study of venetoclax plus RBAC in MCL.

Dr Dreyling on the Recommended Use of Acalabrutinib Plus BR in Pretreated MCL

October 22nd 2025

Martin Dreyling, MD, provides recommendations for use of acalabrutinib plus BR in pretreated MCL based on updated data from the phase 3 ECHO trial.

Dr Visco on the Design of the FIL_V-RBAC Trial of RBAC Plus Venetoclax in High-Risk MCL

October 16th 2025

Carlo Visco, MD, discussed key design elements of the FIL_V-RBAC study of RBAC followed by venetoclax in older patients with high-risk MCL.

Dr Dreyling on Prior Findings From the ECHO Trial of Acalabrutinib Plus BR in Pretreated MCL

October 15th 2025

Martin Dreyling, MD, discusses prior findings and potential implications of the phase 3 ECHO trial of acalabrutinib plus BR in pretreated MCL.

Baseline Cardiovascular Assessment, Monitoring Are Crucial With BTK Inhibitors in CLL and Other Hematologic Malignancies

October 14th 2025

A meta analysis found BTK inhibitors carry risks of hypertension, atrial fibrillation, and hemorrhage, underscoring the need for cardiovascular monitoring.

FDA Grants Breakthrough Therapy Designation to Sonrotoclax for R/R Mantle Cell Lymphoma

October 13th 2025

The FDA granted breakthrough therapy designation to sonrotoclax for relapsed/refractory mantle cell lymphoma.

Real-World Study Shows Highest Treatment Adherence Rates With Zanubrutinib vs Other BTK Inhibitors in MCL

October 13th 2025

Real-world MCL treatment with zanubrutinib generated longer treatment durations and higher treatment adherence rates vs acalabrutinib and ibrutinib.

Removal of REMS Requirements Could Help Streamline CAR T-Cell Therapy Access in Hematologic Cancer Care

October 10th 2025

The removal of REMS programs for approved CAR T-cell therapies could enable improved access and streamlined management of hematologic malignancies.

Ibrutinib Plus Rituximab Shows PFS Benefit Over Chemoimmunotherapy in Untreated MCL

October 10th 2025

Ibrutinib plus rituximab showed a progression-free survival benefit vs standard chemoimmunotherapy in older patients with untreated mantle cell lymphoma.

Poor Response Rates Persist After Progression on Brexu-Cel in Mantle Cell Lymphoma

October 9th 2025

Patients with MCL who relapsed after brexu-cel had poor survival outcomes, underscoring the need for effective post–CAR T-cell therapy strategies.